paclitaxel + docetaxel + vinflunine

This is a **combination** of three distinct chemotherapeutic agents: paclitaxel, docetaxel, and vinflunine. Each drug individually is a microtubule inhibitor (antimitotic agent) used primarily for the treatment of various solid tumors. - **Paclitaxel** and **docetaxel** are members of the taxane class; they stabilize microtubules and thereby inhibit cell division by blocking mitosis, leading to apoptosis. **Vinflunine** is a novel vinca alkaloid derivative, and like other vinca alkaloids, it inhibits tubulin polymerization, disrupting the formation of microtubules necessary for mitosis and cell division. While these drugs have overlapping mechanisms, their specific molecular interactions with the tubulin/microtubule system differ. This combination is not used as a fixed formulation but may be considered in research or as alternatives within some clinical trials or protocols (e.g., as investigator's choice of single-agent therapy, typically for advanced urothelial cancer as seen in the KEYNOTE-045 trial), but not together as a three-drug regimen[1][2][3][5][6][9].